TIDE Genetics at Cell 2026
Great gene edit.
Now prove it!
TIDE: the Sanger-based method specified for the release of the first-ever approved CRISPR therapy
Event program · Start-up Zone
How do we create a method that makes gene-editing data stand up to review, transfer, and routine use? Jelle ten Hoeve, TIDE Genetics’ CEO, will give a 10-minute talk at Cell 2026, and is ready to discuss gene-editing analysis with you.
The analytical challenge
From research to release, what you need to prove changes
In research, scientists want to know whether an edit worked. In development, the method behind the numbers comes under scrutiny. At batch release, teams must present consistent results and records that inspectors can follow.
One good result is often sufficient in research. However, once the program leaves research, the analytical method must:
- Offer the same answer every time (repeatability).
- Answer the same questions in different labs, including CDMOs and QC teams (transferability).
- Formally show regulators that it works (validation).
Ideally, a single analytical method would meet all those requirements, so it would never need to be replaced along the way. Let’s talk about TIDE.
Did the edit work?
How do you know?
Can you show it every time?
The precedent
The TIDE method comes with evidence
Casgevy was the first CRISPR/Cas9 therapy approved by the FDA. Its public release specification indicates that TIDE was used to measure the on-target editing frequency for both identity and potency. Sanger-based analysis has already carried one CRISPR therapy all the way to release.
The FDA document names the method, not a software product. Each developer still needs to validate the method for their specific assays and implementation.
Read the FDA documentOne analytical method
From the first experiment to regulated work
TIDE quantifies gene-editing efficiency and insertion/deletion (indel) outcomes from Sanger sequencing traces. Choose the workflow that fits your program’s current stage.
TIDE R&D – RESEARCH
Fast and easy-to-use quantitative analysis of gene-editing experiments. Sequencing traces in; editing efficiency and indel profiles out.
Start the TIDE appTIDE GxP – DEVELOPMENT and RELEASE
The same method as in research, but now for regulated workflows, with documents to validate the software, records of who did what, and controlled updates.
Not sure which workflow fits your stage? Talk to us at Stand E.
See you at Cell
Come for the conversation. Stay for the stroopwafels
Meet us at Stand E in the Start-up Zone on 12–13 November. We welcome any conversation about gene-editing analysis, analytical development, and QC. Coffee and Dutch stroopwafels will be waiting for you.
View the Cell 2026 event pagesupport@tidegenetics.com
